ProCE Banner Series

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape

Join us for this case-based, interactive, CME-certified live symposium at ASCO 2024 featuring expert perspectives on molecular testing and targeted therapy for patients with advanced biliary tract cancers. Bring your questions for the live question and answer session with the expert panel.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who treat patients with biliary tract cancer who are candidates for targeted systemic therapy. 

All Events

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape

Past Events

June

01

2024

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

ProCE Banner Faculty
Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

ProCE Banner Faculty
James J. Harding, MD

Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Topics

  • Selecting Initial Treatment for Patients With BTC
  • Targeting BTC Based on Genomic Alteration
  • A Look to the Future: Novel Agents and Targets
  • Highlight of Key ASCO 2024 Abstracts
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve learners’ knowledge, confidence, and competence to manage biliary tract cancer in patients who are candidates for targeted systemic therapy.

Target Audience
This program is intended for medical oncologists and other healthcare professionals who treat patients with biliary tract cancer who are candidates for targeted systemic therapy. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the known genomic alterations in BTC and their impact on disease progression

  • Plan guideline-concordant molecular testing for individual patients with BTC and suspected genomic alterations

  • Choose an appropriate targeted therapy for patients with unresectable/refractory/metastatic BTC based on the results of molecular testing for genomic alterations

  • Educate patients and caregivers about potential enrollment on clinical trials in the case of alterations without an approved or off-label treatment option   

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

A blue and white signDescription automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS). 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.